Probiotics reduce complications induced by interventional therapy in patients with primary hepatic carcinoma and liver cirrhosis

( views:, downloads: )
Author:
CHEN Yu-tang(Department of Interventional Therapy,Zhejiang Cancer Hospital,Hangzhou 310022,China)
SHAO Guo-liang(Department of Interventional Therapy,Zhejiang Cancer Hospital,Hangzhou 310022,China)
SHI Lei(Department of Interventional Therapy,Zhejiang Cancer Hospital,Hangzhou 310022,China)
YAO Zheng(Department of Interventional Therapy,Zhejiang Cancer Hospital,Hangzhou 310022,China)
XIA Qi-rong(Department of Interventional Therapy,Zhejiang Cancer Hospital,Hangzhou 310022,China)
Journal Title:
CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
Issue:
Volume 02, Issue 06, 2009
DOI:
10.3760/cma.j.issn.1674-2397.2009.06.005
Key Word:
Carcinoma,bepatocellular;Probiotics;Transarterial chemoembelization

Abstract: Objective To investigate whether oral administration of probiotics can reduce complications induced by interventional therapy in patients with primary hepatic carcinoma and liver cirrosis.Methods Two hundred and sixty four patients with primary hepatic carcinoma and liver cirrhosis who underwent transarterial chemoembolization(TACE) were randomly divided into two groups.and patients in experimental group were given probiotics but not in control group.Shoa-term clinical manifestations.liver functions,blood routine and pain scores were compared between two groups.Results On the day 3 after therapy,the incidence of abdominal distension and constipation in experimental group were less than that in control group(x2=18.22 and 55.22,P=0.000);On the day 7 after therapy,the incidence of abdominal distension,constipation and infection in experimental group were less than that in control group(x2=5.35,13.5 and 19.14,P=0.021,0.000 and 0.000).There were no significant difference in other clinical manifestations,liver function,blood routine and pain scores between the two groups. Conclusion Oral administration of probiotics can reduce the incidence of some short-term complication induced by interventional therapy in patients with hepatic carcinoma and liver cirrhosis.

  • [1]Wang Jn,Zhou KR.skmdard combined intervention treatment for liver cancer(draft).Linehuang Fangshexue Zazhi,2002,21(7):497-500.(in Chinese)王建华,周康荣.肝癌综合性介入治疗规范化方案(草案).临床放射学杂志,2002,21(7):497-500.
  • [2]Takayasu K,Arii S,Ikai I,et al.Prospective cohort study of transarterial ehemoembolization for unresectable hepatocellular carcinoma in 8510 patients.Gastroenterology,2006,131(2):461-469.
  • [3]Zhang M.The clinical application and development of probiotics.Zhongguo Yiyuan Yongyao Pillgjia yu Fenxi,2008,8(10):797-800.(in Chinese)张玫.益生菌制剂的临床应用和进展.中国医院用药评价与分析,2008,8(10):797-800.
  • [4]Pujol FH,Devesa M.Genotypic variability of hepatitis viruses associated with chronic infection and the development of hepatocellular carcinoma.J Clin Gastroenterol,2005,39(7):611-618.
  • [5]Di Bisceglie AM.Epidemiology and clinical presentation of hepatecellular carcinoma.J Vasc Interv Radiol,2002,13(9 Pt 2):S169-S171.
  • [6]Jia FZ.Hepatopathy and intestinal mieroeeology environment.Zhongguo Shiyong Neike Zazhi,2006,26(13):971-973.(in Chinese)贾辅忠.肝病与肠道微生态环境.中国实用内科杂志,2006,26(13):971-973.
  • [7]Bu SR,Dal YM,Zhao Y,et al.Experimental and clinical study of BIFICO on plasma endotoxin in rats and patients with liver cirrhosis.Zhongguo Weishengtaixue Zazhi,2005,17(2):116-117.(in Chinese)卜淑蕊,戴咏梅,赵严,等.培菲康对肝硬化血浆内毒影响的研究.中国微生态学杂志,2005,17(2):116-117.
  • [8]Zhao HY,Wang HJ,La z,et al.A study of the intestinal micmflora in patients with liver cirrhosis.Zhonghua Xiaohua Zazhi,2003,23(7):407-409.(in Chinese)赵海英,王惠吉,吕治,等.肝硬化患者肠道菌群的研究.中华消化杂志,2003,23(7):407-409.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn